
Quest Diagnostics company profile
$262.21+1.01%Close 16 Nov 2026 · Market value $28.35B
About Quest Diagnostics
Quest Diagnostics is a provider of diagnostic information services, offering clinical laboratory testing, anatomic pathology services, and insights derived from its laboratory results. Its main offerings include routine, non-routine and Advanced Diagnostics tests, along with Collaborative Lab Solutions for hospital laboratories, reference testing, and consumer-initiated testing through QuestHealth.com. Its customers include physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers. The company operates principally in the United States, with approximately 2,400 patient service centers, and also serves customers in other countries through its reference testing business.
A summary of the business section of the company's latest annual report, filed 26 Feb 2026.
Company facts
| Ticker | DGX · NYSE |
|---|
| Sector | Healthcare |
|---|
| Industry | Health Care Services |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 31 December |
|---|
| Reporting currency | USD |
|---|
| CIK | 1022079 |
|---|
| Latest annual report | 10-K, filed 26 Feb 2026 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| James E. Davis | CEO and President · Director | 489K · < 1% | Sale under a 10b5-1 plan, 1 Sep 2026 |
|---|
| Catherine T. Doherty | Executive Vice President | 135K · < 1% | Grant or award, 3 Nov 2026 |
|---|
| Michael E. Prevoznik | SVP & General Counsel | 113K · < 1% | Gift, 28 Aug 2026 |
|---|
| Sam A. Samad | Executive Vice President & CFO | 83.8K · < 1% | Grant or award, 21 Oct 2026 |
|---|
| Karthik Kuppusamy | SVP, Clinical Solutions | 40.8K · < 1% | Code L, 21 Oct 2026 |
|---|
| Timothy L. Main | Director | 24.6K · < 1% | Code L, 21 Oct 2026 |
|---|
| Vicky B. Gregg | Director | 15.4K · < 1% | Grant or award, 21 Oct 2026 |
|---|
| Denise M. Morrison | Director | 6.6K · < 1% | Grant or award, 20 May 2026 |
|---|
| Luis A. Diaz, Jr. | Director | 2.4K · < 1% | Grant or award, 20 May 2026 |
|---|
| Robert B. Carter | Director | 1.5K · < 1% | Code L, 21 Oct 2026 |
|---|
| Wright L. Lassiter III | Director | 1.5K · < 1% | Code L, 21 Oct 2026 |
|---|
| Deppe Michael J | SVP, Corp. Controller & CAO | — | Option exercise, 13 Nov 2026 |
|---|
| Plewman Patrick | SVP for Diagnostic Services | — | Option exercise, 9 Nov 2026 |
|---|
| Ramachandran Subu | SVP, Regional Businesses | — | Grant or award, 3 Nov 2026 |
|---|
| DELANEY MARK E | SVP & Chief Commercial Officer | — | Grant or award, 3 Nov 2026 |
|---|
| Gary M. Pfeiffer | Director | — | Sale under a 10b5-1 plan, 26 Oct 2026 |
|---|
| Tracey C. Doi | Director | — | Grant or award, 20 May 2026 |
|---|
| Timothy M. Ring | Director | — | Grant or award, 20 May 2026 |
|---|
| WENTWORTH TIMOTHY C | Director | — | Grant or award, 20 May 2026 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
DGX in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.